Manulife’s Earnings Beat Was Already Priced In—Now the Comvest Test Begins

The numbers were strong. Manulife delivered a clear beat on its fourth-quarter results, but the market's reaction told a different story. The company reported a core EPS of $1.12 for the quarter, crushing the consensus forecast of $0.76. That's a 47% surprise, a significant gap between reality and the whisper number. For the full year, core earnings hit $7.5 billion, with core EPS growing 8%.

Yet, the stock's immediate response was muted. Despite the robust print, shares saw a slight premarket decline of 0.24% following the report. This disconnect is the core of the expectation gap. The beat was real, but it appears the market had already priced in a strong quarter. The sequence matters: the full-year and Q4 results were formally released in early February 2026, following earlier Form 6-K filings in November and December. By the time the official numbers landed, much of the positive news may have been digested. The stock's slight dip suggests investors were looking past the beat to other factors-perhaps broader market conditions, sector trends, or the need for a new catalyst to drive a rally. In this setup, strong earnings weren't enough to overcome a sense that the good news was already in the price.

Decoding the Drivers: Where Growth Was (and Wasn't) Priced In

The beat on earnings was broad, but the market's focus was on the specifics. The core story was one of strong growth in new business, which appears to have been a key part of the priced-in narrative. For the full year, 2025 APE sales up 14% and new business CSM up 28% were standout performances. This robust new business engine, which also drove an 18% increase in new business value, likely set a high bar for expectations. When the official results confirmed these figures, the market may have seen them as the baseline for a strong year, leaving little room for a positive surprise on the bottom line alone.

The picture in Asia, however, was more volatile and arguably more critical for the stock's forward view. The segment showed significant resilience, with earnings increasing approximately 25% year-over-year in the third quarter of 2025.

Yet, that growth followed a period of weakness, including a 4% quarter-over-quarter decline in Q3 2024. This swing from a dip to a strong rebound likely created uncertainty. The market may have been looking for confirmation that the 25% surge was sustainable, not a one-off. The fact that the full-year results included this strong performance suggests the volatility was already in the price, but the quality of that growth-its durability-was the unspoken question.

Strategically, the acquisition of Comvest Credit Partners was a major development, but its financial impact was not reflected in the 2025 numbers. The deal was announced and expected to close in the fourth quarter of 2025. Since the annual report covers results through December 31, 2025, the financials for that transaction were not yet in the numbers. This timing is crucial. Earlier Form 6-K filings in late 2025, like the one from November, may have set expectations for corporate actions and growth initiatives. But the core financial results in the February 2026 annual report were the final, concrete data point the market used to assess the year. The Comvest deal, while a positive catalyst, was a forward-looking item that could not be priced into the 2025 print itself.

The bottom line is that the market was judging the results against a complex set of expectations. The strong new business metrics were likely already priced in as a given. The Asia segment's recovery was a positive, but its volatility meant it needed to be seen as reliable to drive conviction. And the strategic acquisition, while important, was a future story, not a past one. When all the pieces were assembled, the reality matched the high bar set by the whisper number, leaving the stock to trade on the next catalyst.

The Guidance Reset: What's Next for the Expectation Curve

With the 2025 results in the rearview, the market's focus shifts to the forward view. Management's reaffirmed target of an 18%+ Core ROE by 2027 provides a clear, long-term benchmark. This goal sets a high bar, framing the coming years as a test of execution. The company's strong 2025 performance, with core ROE hitting 17.1%, shows it's on the path. But the expectation gap now is about the pace and sustainability of that climb. The market will be watching for any signs that the company is falling behind or, conversely, accelerating toward that target.

Capital returns underscore the confidence in that trajectory. In 2025, Manulife returned nearly $5.5 billion of capital to shareholders, including a 10.2% dividend increase. This aggressive payout signals management's belief in ample free cash flow generation and its commitment to rewarding investors. For now, this supports the stock, but it also raises the bar for future earnings to justify such returns. Any stumble in growth could force a difficult choice between dividends and reinvestment.

Yet, a key risk to that growth narrative is already in the forecast. The company projects a core earnings decline of approximately 4% in the Canadian segment for 2025. This headwind in its home market could pressure overall earnings expectations, even as other segments like Asia show resilience. It introduces a tension: strong new business and international growth must offset domestic weakness to hit the 2027 ROE target. The market will be parsing each quarterly update for evidence that this Canadian drag is being managed.

The next major catalyst is the Comvest Credit Partners acquisition. The deal was announced and expected to close in the fourth quarter of 2025. Its financial impact is not in the 2025 numbers but will be a critical test of the company's strategic execution. If Comvest integrates smoothly and begins contributing to earnings and the ROE target, it could reset expectations higher. If integration proves costly or slow, it could become a drag, adding to the pressure from the Canadian segment.

The bottom line is that the expectation curve has been reset. The 2025 beat was a baseline. The market's next watchpoints are clear: the impact of the Comvest deal on the balance sheet and earnings, and the execution needed to close the gap to that 18%+ ROE target by 2027. The path forward is less about beating whispers and more about meeting the new, higher standard set by management.